Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
Details : Xenical is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2023
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Exploring the Supportive Effect of Acarbose in Weight Management
Details : Orlistat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 06, 2023
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mg
Details : Orlistat is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Orlistat
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orlistat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 21, 2020
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orlistat is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 10, 2019
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase IV
Sponsor : Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Weight Loss Aid in an Exposed Population
Details : Orlistat is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Polybrominated Biphenyl Poisoning.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 11, 2018
Lead Product(s) : Orlistat
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase IV
Sponsor : Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orlistat is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 11, 2016
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity
Details : Orlistat is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Overweight.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 20, 2015
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Hamell
Deal Size : Inapplicable
Deal Type : Inapplicable
Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.
Details : Orlistat is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Weight Loss.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 19, 2014
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Hamell
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Orlistat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 24, 2014
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
